About Us
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Beyond CD4 counts: Multi-biomarker assessment of estimated time since HIV-1 infection and risk factors for late diagnosis.

Researchers

Kathleen Smith, Macauley Locke, Emmi Andersson, Sandra Broddesson, Christina Carlander, Aylin Yilmaz, Jan Albert, Thomas Leitner, Johanna Brännström

Abstract

Late diagnosis (LD) of HIV, defined as CD4 count <350 cells/μL or AIDS at diagnosis, remains a substantial public health challenge, with half of individuals in Europe diagnosed late. How long these individuals have lived with HIV remains unclear. We applied a multi-biomarker model (MBM) to estimate the time since infection (ETI) in newly diagnosed individuals classified as LD. We conducted a prospective cohort study of newly diagnosed people with HIV in Sweden between November 2017 and December 2022. Individuals were classified as LD or non-LD according to an updated consensus definition. We applied an MBM combining CD4 count, pol polymorphism counts, pol next-generation sequencing diversity, HIV-1 limiting-antigen avidity assay and last negative HIV test to probabilistically derive ETI distributions. More than half (52.4%) were classified as LD. Risk factors for LD included age >50 years (adjusted odds ratio (aOR) 2.94, 95% CI 1.42-6.09), origin in Asia and Pacific (aOR 4.53, 95% CI 1.81-11.32) and HIV acquisition in Asia and Pacific (aOR 2.28, 95% CI 1.08-4.83). Men who have sex with men had reduced risk of LD versus persons with heterosexual acquisition (aOR 0.38, 95% CI 0.22-0.64). ETI in 344 individuals revealed diagnostic delays; 41% (95% CrI 36.7-46.0) were diagnosed within 1 year: 71% of non-LDs (CrI 95% 65.0-77.7) versus 12% of LDs (95% CrI 8.4-16.2). Among LDs, over 60% remained undiagnosed beyond 3 years. Multi-biomarker ETI reveals that most HIV-1 infections remain undiagnosed for over 1 year. The updated LD definition correlates better with time since infection and ETI distributions show substantial diagnostic delays. Expanded testing strategies targeting heterosexual and older populations are urgently needed.
Source: PubMed (PMID: 42836675)View Original on PubMed